Myocardial ischemia-reperfusion enhances transcriptional expression of endothelin-1 and vasoconstrictor ET<sub>B</sub> receptors via the protein kinase MEK-ERK1/2 signaling pathway in rat by Skovsted, Gry Freja et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Myocardial ischemia-reperfusion enhances transcriptional expression of endothelin-1
and vasoconstrictor ETB receptors via the protein kinase MEK-ERK1/2 signaling
pathway in rat
Skovsted, Gry Freja; Kruse, Lars Schack; Berchtold, Lukas Adrian; Grell, Anne-Sofie;
Warfvinge, Karin; Edvinsson, Lars
Published in:
PLOS ONE
DOI:
10.1371/journal.pone.0174119
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Skovsted, G. F., Kruse, L. S., Berchtold, L. A., Grell, A-S., Warfvinge, K., & Edvinsson, L. (2017). Myocardial
ischemia-reperfusion enhances transcriptional expression of endothelin-1 and vasoconstrictor ETB receptors viathe protein kinase MEK-ERK1/2 signaling pathway in rat. PLOS ONE, 12(3), [e0174119].
https://doi.org/10.1371/journal.pone.0174119
Download date: 03. Feb. 2020
RESEARCH ARTICLE
Myocardial ischemia-reperfusion enhances
transcriptional expression of endothelin-1
and vasoconstrictor ETB receptors via the
protein kinase MEK-ERK1/2 signaling pathway
in rat
Gry Freja Skovsted1¤*, Lars Schack Kruse1, Lukas Adrian Berchtold2, Anne-Sofie Grell1,
Karin Warfvinge1, Lars Edvinsson1,3
1 Department of Clinical Experimental Research, Glostrup Research Institute, Rigshospitalet, University of
Copenhagen, Glostrup, Denmark, 2 Department of Biomedical Sciences, Cellular and Metabolic Research
Section, University of Copenhagen, Copenhagen, Denmark, 3 Department of Medicine, Institute of Clinical
Sciences in Lund, Lund University, Lund, Sweden
¤ Current address: Department of Veterinary and Animal Sciences, Section of Experimental Animal Models,
Faculty of Health and Medical Sciences, University of Copenhagen, Frederiksberg C, Denmark
* gryfreja@sund.ku.dk
Abstract
Background
Coronary artery remodelling and vasospasm is a complication of acute myocardial ischemia
and reperfusion. The underlying mechanisms are complex, but the vasoconstrictor peptide
endothelin-1 is suggested to have an important role. This study aimed to determine whether
the expression of endothelin-1 and its receptors are regulated in the myocardium and in cor-
onary arteries after experimental ischemia-reperfusion. Furthermore, we evaluated whether
treatment with a specific MEK1/2 inhibitor, U0126, modified the expression and function of
these proteins.
Methods and findings
Sprague-Dawley rats were randomly divided into three groups: sham-operated, ischemia-
reperfusion with vehicle treatment and ischemia-reperfusion with U0126 treatment. Ische-
mia was induced by ligating the left anterior descending coronary artery for 30 minutes fol-
lowed by reperfusion. U0126 was administered before ischemia and repeated 6 hours after
start of reperfusion. The contractile properties of isolated coronary arteries to endothelin-1
and sarafotoxin 6c were evaluated using wire-myography. The gene expression of endothe-
lin-1 and endothelin receptors were measured using qPCR. Distribution and localization of
proteins (pERK1/2, prepro-endothelin-1, endothelin-1, and endothelin ETA and ETB recep-
tors) were analysed by Western blot and immunohistochemistry. We found that pERK1/2
was significantly augmented in the ischemic area 3 hours after ischemia-reperfusion; this
correlated with increased ETB receptor and ET-1 gene expressions in ischemic myocardium
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and in coronary arteries. ETB receptor-mediated vasoconstriction was observed to be
increased in coronary arteries 24 hours after ischemia-reperfusion. Treatment with U0126
reduced pERK1/2, expression of ET-1 and ETB receptor, and ETB receptor-mediated
vasoconstriction.
Conclusions
These findings suggest that the MEK-ERK1/2 signaling pathway is important for regulating
endothelin-1 and ETB receptors in myocardium and coronary arteries after ischemia-reper-
fusion in the ischemic region. Inhibition of the MEK-ERK1/2 pathway may provide a novel
target for reducing ischemia-reperfusion damage in the heart.
Introduction
Acute myocardial infarction (AMI) is the most common cause of death, with a mortality of
more than 6 million people each year worldwide [1]. Treatment strategies aim to restore blood
flow using thrombolytic therapy or direct angioplasty with stenting of the affected arteries via
percutaneous coronary intervention (PCI). Paradoxically, in addition to the direct ischemic
injury, restoring the blood flow can cause damage to the tissue further limiting the beneficial
effects of myocardial reperfusion. This phenomenon, termed reperfusion injury, is associated
with death of cardiomyocytes that were viable immediately before myocardial reperfusion [2].
The pathogenesis of reperfusion injury involves the interplay of multiple mechanisms, includ-
ing the release of vasoconstrictors, the no-reflow phenomenon, a profound inflammatory
response, apoptosis, and necrosis [3–5]. The coronary vascular endothelium is sensitive to
ischemia-reperfusion injury, as manifested by decreased endothelium-dependent vasorelaxa-
tion in some models [6], but not in the present model which has been described earlier
(Skovsted et al. 2014). Comparatively less is known on how ischemia-reperfusion (IR) injury
affects the smooth muscle cells in the coronary artery per se and in the adjacent myocardium.
The endothelin-1 (ET-1) peptide is an important participant in the pathophysiology of cor-
onary artery disease and myocardial infarction [7]. This peptide is one of the most potent
endogenous vasoconstrictors known at present, and it is synthesized and released from vascu-
lar and endocardial endothelial cells and from myocytes [8–11]. ET-1 contributes to the regu-
lation of both coronary and peripheral vascular tone [12,13] through its activation of the
contractile ETA and relaxant ETB receptors. Moreover, ET-1 release increases during myocar-
dial ischemia and reperfusion, further aggravating this condition. Notably, the plasma levels of
ET-1 are increased in patients with coronary artery vasospasm, following myocardial infarc-
tion, and in congestive heart failure [14–18]. The vasoconstrictor response to ET-1 is primarily
mediated by ETA receptors in vascular smooth muscle cells (VSMCs), and the vasodilator
effect is mediated by ETB receptors located in the endothelium [19–21]. We have reported pre-
viously on the phenotypic change from relaxant to contractile coronary artery ETB receptors
expressed in VSMCs and its increase in human coronary arteries after a fatal myocardial
infarct [22] and after experimental myocardial IR in vivo [23]. Organ culture of coronary arter-
ies has been used as a surrogate method to study mechanisms involved in the phenotypic alter-
ations of vessel wall receptors. The up-regulation of VSMC ETB receptors is mediated through
an increase in transcription and/or translation via the mitogen-activated protein kinase/extra-
cellular signal-regulated kinase (MEK-ERK1/2) signaling pathway [24].
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The aim of the present study was to investigate whether the MEK-ERK1/2 signaling path-
way is activated early after an IR episode. Furthermore, if this pathway is involved in regulating
the expression of ET-1 and endothelin receptors in rat coronary arteries and myocardium
after IR using an in vivo method, and whether an activation could be attenuated by the MEK1/
2 inhibitor U0126.
Methods
Animals
Male Sprague-Dawley rats (11–14 weeks old, 330–415 g) were obtained from Taconic, Den-
mark. The rats were provided with standard rat chow and water ad libitum and were housed in
a reversed 12 h light/12 h dark condition. All experimental procedures were performed in
accordance with national laws and guidelines, and were approved by the Danish Animal
Experimentation Board (2012/561-162).
Experimental protocol
A total of 48 rats were used in the study. They were anesthetized with an induction dose (2.5
ml/kg) of a mixture of Hypnorm-Midazolam (1:1:2) in sterile water (containing 0.079 mg/ml
fentanyl, 2.50 mg/ml fluanison, Hypnorm1, VetaPharma Ltd, UK, and 1.25 mg/ml, Midazo-
lam “Hameln”, Hameln, Germany). Anesthesia was maintained using supplementary doses of
Hypnorm-Midazolam (1.0 ml/kg) every 20 to 40 minutes. During the surgical procedure, rats
were artificially ventilated (75 cycles/min, tidal volume 10 ml air/kg) with a rodent ventilator
(Ugo Basile Rodent Ventilator, Comerico, Italy), and body temperature was maintained at
37˚C.
Ischemia was induced by ligation of the left anterior descending artery (LAD) for 30 min-
utes followed by reperfusion or non-occlusion (sham) as described previously [23]. Briefly, the
chest was opened through a left thoracotomy, and the heart was exposed by making an incision
in the pericardium. A suture was passed around the LAD approximately 4–5 mm away from
its origin and tightened. Regional myocardial ischemia was confirmed visually and ST segment
elevation was seen on the ECG. After 30 min of ischemia, the ligature was released and the tis-
sue was reperfused. The chest was closed and air was sucked out of the thorax. Thereafter, rats
were allowed to recover on a heating pad (37˚C) and were extubated when they showed nor-
mal spontaneous breathing. For post-operative analgesia and to supplement their fluids, the
rats were subcutaneously administered 5 mg/kg carprofen (Rimadyl Vet, Pfizer), 0.03 mg/kg
buprenorfin (Temgesic, Schering-Plugh, Brussels, Belgium), and 5 ml 0.9% NaCl isotonic solu-
tion immediately after surgery.
The rats were randomly divided into three groups: sham, IR with DMSO (vehicle) and IR
with 1,4-diamino-2,3-dicyano-1,4 bis [2-aminophenylthio] butadiene (U0126). Rats were
given intraperitoneal injections of U0126 (LC labs, Boston, MA, USA) (30 mg/kg) dissolved in
DMSO (Sigma, St Louis, MO, USA) (1.5 ml/kg) or 500 μl DMSO (1.5 ml/kg) 30 min before
ischemia and again subcutaneously 6 hours after reperfusion (Fig 1). Rats were euthanized
using CO2 sedation and decapitation at either 3 h or 24 h of reperfusion. Rats in the 24-h
groups were also treated with a per-oral formulation of buprenorphine (Temgesic, Schering-
Plough, Brussels, Belgium) 0.4 mg/kg in 5 mg Nutella1.
Vessel isolation
The heart was immediately after decapitation excised and placed in oxygenated ice-cold physi-
ological saline solution (PSS in mM): 119 NaCl, 4.7 KCl, 2.5 CaCl2, 25 NaHCO3, 1.17 MgSO4,
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1.18 KH2PO4, 5.5 glucose and 0.03 EDTA with 5% CO2. LAD and septal coronary arteries (SCA,
internal control) were removed by dissecting the tissue around the vessel wall. LAD was divided
into two approximately 2-mm segments, one upstream and one downstream of the ligature [23].
SCA segment was dissected out approximately 2–4 mm away from its origin. The endothelium
was removed gently by passing a human hair through lumen of the artery segments.
Functional ex vivo studies
Coronary artery segments from 13 rats (n = 6 in the 24 h IR vehicle group and n = 7 in the 24
h IR U0126 group) were mounted in a wire myograph and stretched to their optimal lumen
diameter to obtain optimal conditions for active tension development [23]. ETB receptor-
mediated responses were investigated using the sarafotoxin 6c (S6c) peptide, which exhibits
high selectivity for ETB receptors compared to ETA receptors [25]. The ETA receptor-mediated
response was investigated on the same artery segments after S6c (NeoMPS, Strassbourg,
France) by adding ET-1 (NeoMPS, Strasbourg, France) at a concentration range from 10 pM
Fig 1. Experimental protocol. A total of 48 rats were allocated into 3 surgery groups: sham, IR+vehicle, and IR+U0126. Rats in the vehicleand U0126
-treatment groups were given intraperitoneal injections with 500 μl DMSO or U0126 (30 mg/kg), respectively, 30 min before ischemia and again
subcutaneously 6 hours after reperfusion. Rats were euthanized after either 3 h or 24 h of reperfusion.
https://doi.org/10.1371/journal.pone.0174119.g001
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to 0.1 μM. Before adding ET-1, the arteries were pretreated with the specific endothelin ETB
receptor antagonist BQ788 (0.9 μM, Sigma, St. Louis, MO, USA) for 30 min. Before each con-
centration-response curve was determined, the VSMC contractile function was confirmed by
challenging the segments two or three times with 125 mM K+ (KPSS; similar to PSS except
that NaCl was exchanged for KCl on an equimolar basis).
Endothelium function was determined on all artery segments by assessing their relaxation to
the acetylcholine receptor agonist carbachol (10 μM) after obtaining steady-state pre-contraction
tone with prostaglandin F2α (PGF2α) (10 μM). Carbachol-induced relaxation that was<10% of
the prostaglandin-induced vasoconstriction was defined as non-functional endothelium.
After the last concentration-response curve was determined, the maximal contractile capac-
ity of each artery was assessed by the addition of a cocktail solution [KPSS plus 10 μM PGF2α
and 10 μM 5-hydroxytryptamine (5-HT)].
Quantitative RT-PCR
Myocardial tissue from the infarcted area of the left ventricle that was downstream of the liga-
ture was isolated from 21 rats (n = 5, 3 h sham group; n = 8, 3 h IR vehicle group; n = 8, 3 h IR
U0126 group). The tissue was homogenized using lysing matrices in a FastPrep Cell Disrupter
(ThermoSavant) for 3 × 20 s. To prevent heating and degradation, the samples were cooled
on ice for a couple of seconds in between each 20-s pulse. RNA extraction was performed
according to the NucleoSpin miRNA kit manual from Macherey-Nagel. cDNA was synthe-
sized using an iScript cDNA synthesis kit (BioRad). The real-time PCR amplification was per-
formed with SYBR1 Select Master Mix (Life Technologies) using the following primer sets:
Ednra (PPR45119A), Ednrb (PPR45420C), and Ppia (PPR06054A) from Qiagen, and ET-1 for-
ward (GAAACAGCTGTCTTGGGAGCAGA) and reverse (CCTTGTCCATCAAGGAGGAGC) from
Eurofins. The manufacturer’s guidelines (Qiagen) for the PCR reaction conditions were fol-
lowed using a ViiA7 PCR machine (Applied Biosystems). The quantity of each gene transcript
was quantified using standard curves and normalized to peptidylprolyl isomerase A (Ppia).
Western blot analysis
Myocardial tissue from the infarcted area of the left ventricle downstream of the ligature was
isolated from 26 rats (n = 4, 3 h sham group; n = 4, 3 h IR vehicle group; n = 4, 3 h IR U0126
group; n = 4, 24 h sham group; n = 5, 24 h IR vehicle group; n = 5, 24 h IR U0126 group).
After isolation, the tissues were stored at -80˚C. For analysis, samples were immersed in 300 μl
modified RIPA buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 50 mM beta-glycerol-
phosphate, 1% NP-40, 0.1% deoxycholate, 0.1% SDS and 0.5% Triton X-100) containing Com-
plete1 Protease Inhibitor and PhosStop cocktails (both from Roche, Hvidovre, Denmark)
before sonication (2 × 10 1-s pulses, with intermittent cooling on ice, and then 15 s of constant
sonication). The resulting lysate was pre-cleared by centrifugation (18,000 × g at 4˚C for 15
min). The supernatants were transferred to new tubes, and the total protein concentration was
determined using the BioRad DC kit (BioRad Laboratories, Copenhagen, Denmark) and a
Tecan M200 spectrophotometer at 750 nm. Samples were adjusted to 20 μg total protein and
dissolved in LDS buffer (Expedeon, San Diego, USA) containing 50 mM DTT.
Proteins were separated by gel electrophoresis on 4–20% RunBlue gradient gels (Expedeon,
San Diego, USA) at a maximum of 180 V and 150 mA for approximately 1 h 10 min. After
electrophoresis, gels were equilibrated briefly in Tris-glycine transfer buffer (2.9 g Trizma-base
plus 14.4 g glycine/l, 20% ethanol, and 0.1% SDS diluted in MilliQ water) before transfer to
ECL Hybond PVDF membranes (GE Healthcare Life Sciences, Brøndby, Denmark) using wet
blotting for 1 h 20 min (maximum settings, 150 V and 350 mA). Membranes were subsequently
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blocked for 1 h in 2% ECL Prime Blocking Agent (GE Healthcare Life Sciences, Brøndby, Den-
mark) in TBS-T (TBS plus 0.1% Tween 20) before incubation overnight at 4˚C on a rotor with
the following primary antibodies diluted in TBS-T containing 0.02% sodium azide: polyclonal
rabbit-anti-endothelin ETB receptor antibody (#AER-002, Alomone Laboratories, Israel 1:200);
monoclonal mouse-anti-ET-1 antibody (#ab2786, Abcam, 1:1000); polyclonal rabbit-anti-
endothelin ETA receptor antibody (#9780, Sigma, 1:1000); rabbit monoclonal anti-total-ERK
antibody (#9101, Cell Signaling, 1:2000); or mouse monoclonal anti-pERK antibody (#9107,
Cell Signaling, 1:1000). The next day, membranes were washed briefly twice in TBS-T before
incubation for 1 h at room temperature with secondary antibodies in TBS-T: either HRP-conju-
gated donkey-anti-rabbit antibody, 1:40,000 (NA9340V, GE Lifesciences, Brøndby, Denmark)
or HRP-conjugated goat-anti-mouse antibody, 1:20,000 (#1858413, Thermo Scientific Pierce,
Slangerup, Denmark). Finally, the membranes were washed a minimum of 5 × 5 minutes in
large volumes of TBS-T before development using ECL Select Western Blot Detection Kit (GE
Lifesciences, Copenhagen, Denmark) for 5 min at room temperature. Image capture was per-
formed using a Fujifilm LAS-4000 imaging unit (Fujifilm, Japan).
To quantify the relative band intensity, the signals were first normalized to GAPDH as an
internal loading control and then compared using MultiGauge 3.2 software (Fujifilm, Japan).
GAPDH was chosen as a loading control after it was tested for variability in a screen of five
possible loading control candidates in an ischemia model (data not shown).
Co-immunoprecipitation
Freshly isolated myocardium, including the LAD, was homogenized in modified RIPA buffer
by sonication (2 × 10 pulses, 30% output power) followed by freezing on dry ice for approxi-
mately 1 h and then sonication again. Residual cellular debris was removed by centrifugation
(18,000 × g for 15 min at 4˚C). Protein concentration measured using the Bio-Rad DC kit;
50 μg of total protein was used for immunoprecipitation (IP), and 25 μg was used as an input
control. Each IP reaction was adjusted to a total volume of 300 μl in microfuge tubes by the
addition of lysis buffer containing protease and phosphatase inhibitors. Finally, 2 μl of mouse
monoclonal anti-ET-1 antibody (#ab2786, abcam, 2.5 μg/μl) was added. Tubes were incubated
for approximately 15 h at 4˚C on a rotor. The next day, 50 μl of a 50:50 slurry of Protein A/G
Sepharose beads resuspended in lysis buffer was added to each IP reaction for 1.5 h. The beads
were resuspended in LDS buffer that contained 50 mM DTT. The resulting co-IP reaction and
input controls were analyzed as described in the ‘Western blot analysis’ section using rabbit-
anti-ETA antibody (#9780, Sigma, 1:500) as the primary antibody and donkey-anti-rabbit anti-
body (NAV931, GE Lifescience, 1:40.000) as the secondary antibody. Blots were developed
using ECL Select followed by LAS-4000 image capture.
Immunohistochemistry
Immunohistochemical staining was performed on heart tissue that were downstream of the
ligature. Tissue from 16 rats (n = 5, 24 h sham group; n = 5 24 h IR U0126 group; and n = 6, 24
h IR vehicle group) were analyzed. The heart tissues were embedded in Tissue-Tek1, frozen
on dry ice, and stored at -80˚C until further processing. The frozen hearts were sectioned
(10 μm) on a cryostat (Leica, Denmark) and mounted on microscope slides (SuperFrost1,
Menzel, Germany). The sections were fixed for 20 min using Stefanini’s fixative (2% parafor-
maldehyde and 0.2% picric acid in phosphate buffer, pH 7.2) and permeabilized in phosphate
buffered saline (PBS) containing 0.25% Triton X-100 (T-PBS). To prevent nonspecific staining,
sections were blocked with 2% donkey serum and 1% bovine serum albumin (BSA) in T-PBS
for 1 h. Samples were incubated at 4˚C overnight with primary mouse anti-phosphorylated
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ERK1/2 antibody (1:200, ab50011, Abcam, Cambridge, UK), sheep anti-endothelin ETB recep-
tor antibody (1:250, alx-210-506a, Alexis Biochemicals, Nottingham, UK) or mouse anti-ET-1
antibody (1:100, ab2786, abcam) diluted in T-PBS. The following day, the slides were rinsed
three times in T-PBS and incubated with secondary donkey anti-sheep Texas Red antibody
(1:200, Jackson ImmunoResearch, UK) or secondary donkey anti-mouse FITC (1:100, Jackson
Immunoresearch Laboratories) for 1 h in room temperature followed by three washes in T-PBS
before mounting with Vectashield (Vector Laboratories, Burlingame, CA, USA) medium con-
taining 4’, 6-diamino-2-phenylindole (DAPI, nucleus staining). Primary antibody was omitted
as a negative control.
Myocardial infarction
Blood was collected from aorta of the decapitated rats in BD Vacutainer1SSTTM serum tubes
(BD Plymouth, UK) at 24h after LAD ligation or sham operation (n = 6 in each group). The
blood samples were centrifuged and the serum was immediately stored at -80˚C. Serum tropo-
nin T was quantified with electrochemiluminescence immunoassay (Elecsys Troponin T
STAT 4. gen) at Cobas1 6000 analyzer series (Roche1, Indianapolis, US).
Statistical analysis
All concentration-response curves were analyzed by non-linear regression analysis using
GraphPad Prism 5.03 (GraphPad Corp, SanDiego, CA, USA). Each regression line was fitted
to a sigmoid equation: Y = bottom + (top-bottom)/(1+10^((LogEC50-X)
Hill Slope)). In this
equation, X is the log of the agonist concentration, Y is the contractile response developed by
the agonist and normalized to the cocktail response, ‘bottom’ is the initial contractile response
(basal tone), and ‘top’ is the top plateau of the concentration response curve induced by the
agonist. ‘Hill Slope’ describes the steepness of the curve. Emax is the difference between the top
and bottom normalized to the cocktail response, and sensitivity to the agonist is expressed as
the negative logarithm of the molar concentration of the agonist that elicited 50% of the maxi-
mum contraction (pEC50). The results are reported as the mean ± standard error of the mean
(SEM); n denotes the number of rats. Statistical analysis of qPCR, Western blot and serum
Troponin T were performed by one-way ANOVA followed by Bonferroni’s multiple compari-
son test. Coronary contraction in response to S6c or ET-1 were compared in the different vas-
cular segments by two-way repeated-measures ANOVA followed by Bonferroni post-test
(when applicable). Differences were considered statistically significant for P< 0.05.
Results
IR treatment groups
Rats underwent IR according to the protocol shown in Fig 1. The three surgery groups were:
sham operated group, IR vehicle group, and IR with U0126 (i.p. 30 mg/kg) group. Rats were
treated with vehicle only or U0126 (s.c. 30 mg/kg) 30 min before occlusion and 6 h after reper-
fusion and euthanized either 3 h or 24 h after start of reperfusion. During the surgical proce-
dure, rats were monitored with ECG electrodes. Immediately after the LAD occlusion, the
ECG changed to a typical pattern with ST-elevation that persisted during the ischemic period.
After reperfusion, the ST-elevation gradually normalized within 3 h (data not shown).
Protein kinase activation / phosphorylated ERK1/2 analysis
To determine whether IR induced activation of the MEK-ERK1/2 signaling pathway, we per-
formed phospho-specific Western blot analysis of homogenates of myocardial tissue that
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contained a segment of LAD downstream of the occlusion. Quantitative analysis of phos-
phorylated (p) ERK1/2 revealed a significant increase after ischemia at 3 h of reperfusion
(p<0.001), which was significantly attenuated by MEK1/2 inhibitor U0126 (p<0.01). At 24 h
of reperfusion, no difference was observed for pERK1/2 between sham, vehicle or U0126
groups (Fig 2A).
Endothelin expression levels
There was a strong increase in ET-1 expression in the LAD and myocardium segments distal
to ligation in rats subjected to IR and vehicle treatment (Fig 3). The ET-1 mRNA (Fig 3A) level
was measured by qPCR and found to be significantly elevated at 3 h of reperfusion (p<0.001).
Treatment with U0126 significantly reduced the expression of ET-1 mRNA (p<0.005). In the
vehicle treated animals, immunohistochemistry revealed an increase of ET-1 expression in
VSMCs and in the myocardiumafter 3 h of reperfusion compared to sham. This elevated
expression was decreased in animals treated with U0126 (Fig 3B).
Western blot analysis using an antibody against an epitope containing amino acids 8–16 of
ET-1 showed the presence of the prepro-ET-1 peptide (Fig 3C). In contrast to the mature form
of ET-1, which is too small to be detected, prepro-ET-1-like reactivity appeared as a 30-kDa
band. Quantification of the Western blots revealed a significantly increased prepro-ET-1 level
at 3 h of reperfusion as well as a non-significant (p = 0.06) increase at 24 h of reperfusion. The
Fig 2. Western blot analysis of heart homogenates that contained myocardium and the left anterior descending artery (LAD). A. There was a
significant increase in ERK1/2 phosphorylation as normalized to the total ERK1/2 at 3 h of reperfusion, and this was significantly attenuated by treatment
with U0126. After 24 h, phospho-ERK levels had returned to baseline and no changes were seen between the groups. Western blot results are shown as dot
plots, where each dot represent an individual rat (n = 4–5). Bars and whiskers indicate mean values ± SEM. *P < 0.05, ***P < 0.001, one-way ANOVA with
Bonferroni’s multiple comparison test.
https://doi.org/10.1371/journal.pone.0174119.g002
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Fig 3. (A) The mRNA expression levels of ET-1 were sigificantly upregulated at 3 h of IR. U0126 treatment decreased ET-1 mRNA levels
significantly compared to vehicle treatment. Results are shown as whisker plots, with whiskers indicating SEM (n = 5–8), ** P 0.01,
***P 0.001, one-way ANOVA with Bonferroni’s multiple comparison test. B. Protein immunohistochemistry of LAD (left column, arrows)
and myocardium (right column) revealed an increase of ET-1 expression in the vehicle treatment after 24 h of IR. This elavated expression
was decreased after treatment with U0126 in both LAD and in the myocardium. (C) Western blot analysis revealed a significant increase in
prepro-ET-1 protein levels (30 kDa) at 3 h of IR, and the same trend was observed at 24 h of IR. The results are shown as Whisker box plots,
with bars and whiskers indicating mean values ± SEM (n = 4–5). ** P 0.01, one-way ANOVA with Bonferroni’s multiple comparison test.
https://doi.org/10.1371/journal.pone.0174119.g003
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pattern of changes were similar at the two time-points. We found no significant differences in
prepro-ET-1 peptide levels in rats treated with U0126 compared to sham-treated animals at 3
and 24 h of reperfusion, thus it had normalized to the sham level (Fig 3C).
Coronary artery vasomotor responses
In order to measure the vasoconstrictor responses independent of endothelial function, the
endothelial layer was removed gently after the coronary artery segments were dissected free of
adjacent myocardial tissue. The absence of endothelial function was confirmed by a lack of car-
bachol-induced relaxation in pre-constricted artery segments. The average contractile capacity
responses measured after adding the pharmacological cocktail [KPSS+ 5-HT (10 μM) plus
PGF2α (10 μM)] were not significantly different in the SCA compared with those in the LAD,
and there was no difference in the contractile capacity of coronary artery segments from rats
treated with vehicle versus U0126 (data not shown).
Endothelin receptor pharmacology
The vasoconstrictor responses to S6c and ET-1 (the latter after de-sensitization of the ETB
receptors; Skovsted et al. 2014, Adner et al. 1996) were studied in endothelium-denuded coro-
nary artery segments isolated 24 h after IR (Fig 4). S6c induced negligible vasoconstriction in
non-ischemic coronary artery segments (LAD segments upstream of the occlusion and SCA
segments) (Skovsted et al. 2014). In contrast, strong S6c-induced vasoconstriction was seen
in distal coronary artery segments isolated from the ischemic zone downstream of the occlu-
sion in vehicle-treated animals (Fig 4A). U0126 treatment abolished IR-induced functional
increases in ETB receptor-mediated vasoconstrictor responses in downstream artery segments
(Fig 4B).
The ETA receptor-mediated responses to ET-1 were strong and concentration-dependent.
In general, the LAD segments from both vehicle- and U0126-treated rats were slightly more
sensitive to ET-1 than those of the SCA (Fig 4C and 4D). However, there were no changes in
vasoconstrictor responses in LAD segments from the post-ischemic zone compared to the
non-ischemic zone, and U0126 did not modify ETA-receptor-mediated contractions (Fig 4C
and 4D).
Endothelin receptor expression
ETA receptor. We found no significant changes in ETA receptor mRNA expression at 3 h
of reperfusion in any of the experimental groups (Fig 5A). In addition, there were no changes
in the levels of the full-length (45 kDa) ETA receptor protein as analyzed by Western blot at 3
or 24 h (Fig 5B). However, a low molecular-weight band at 30 kDa generally showed up-regu-
lation at 3 h of reperfusion, and up-regulation was partly retained after 24 h of reperfusion (Fig
5C). Interestingly, this low molecular weight ETA receptor-like immunoreactive protein
bound to ET-1, since this band was observed exclusively as a co-immunoprecipitated protein
using an antibody targeting ET-1; it was absent when the antibody was omitted from the co-
immunoprecipitation reaction (Fig 5D, lanes 3 and 2, respectively).
ETB receptor. In post-ischemic LAD and adjacent myocardial tissue, ETB receptor
mRNA had increased significantly at 3 h after reperfusion (Fig 6A). ETB receptor protein levels
increased significantly at 3 h of reperfusion, as compared to sham, however afterU0126 treat-
ment ETB receptor protein level was no significantly increased compared to sham. The ETB
receptor expression showed a similar pattern after 24 h of reperfusion compared to tissue from
sham-operated rats (Fig 6B). With immunohistochemistry we found increased ETB receptor-
like immunoreactivity that localized exclusively to VSMC of LAD coronary arteries after 24 h
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of reperfusion (Fig 6C). Treatment with U0126 attenuated the significant changes in ETB
receptor mRNA expression (Fig 6A). The ETB receptor-like immunoreactivity in VSMCs
found in the vehicle group was abolished in the U0126 group (Fig 6C). As expected there was a
weak ETB receptor expression in the endothelium but this was unaltered by IR (Fig 6C). The
adjacent myocardium did not show any changes in the expression of ETB receptors.
Myocardial infarction
Myocardial ischemic damage was measured as serum levels of cardiac troponin T.We observed
that LAD ligation resulted in a marked significant increase in serum Troponin T levels, but
U0126 showed no a reduction in the serum troponin T level (Fig 7).
Fig 4. Concentration-response curves show the effect of increasing concentrations of Sarafotoxin 6c (S6c) in the left anterior descending artery (LAD)
upstream of the ligature, LAD downstream of the ligature, and non-ischemic septal coronary artery (SCA) after treatment with (A) IR and vehicle or (B)
U0126. The results are shown as mean values ± SEM (n = 6–7), ***P < 0.001; two-way ANOVA with repeated measurements; LAD downstream vs.
upstream. Concentration-response curves show the effect of increasing concentrations of endothelin-1 (ET-1) after ETB receptor desensitization and BQ788
treatment in the LAD upstream of the ligature, LAD downstream of the ligature, and non-ischemic SCA after treatment with (C) the vehicle or (D) U0126. The
results are shown as mean values ± SEM (n = 4–7), ***P < 0.001; two-way ANOVA with repeated measurements; LAD downstream vs. upstream.
https://doi.org/10.1371/journal.pone.0174119.g004
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Discussion
The present study is the first to demonstrate in vivo that IR up-regulates the expression of both
ETB receptors and cellular ET-1 in the distal post-ischemic part of the occluded artery wall of
the LAD and in adjacent myocardium, and that this process is regulated by the MEK-ERK1/2
Fig 5. (A) mRNA expression levels of ETAR in homogenates of the myocardium and left anterior descending artery (LAD) from sham, IR, or IR and U0126
treated rats at 3 h of reperfusion. No significant changes in ETAR mRNA expression were found between the sham, IR, and IR+U0126 groups (one-way
ANOVA post-Bonferroni’s multiple comparison test). Results are expressed as whisker box plots (n = 5–8). (B) Two ETAR-like immunoreactive bands were
observed. The upper (higher molecular weight) band, corresponding to full-length ETAR (45 kDa), did not show any changes in overall expression level
regardless of treatment and reperfusion duration (one-way ANOVA post-Bonferroni’s multiple comparison test). Results are shown as Whisker boxplots,
(n = 4–5). (C) The lower molecular-weight band (30 kDa), generally showed strong up-regulation at 3 h of reperfusion, and this was partly retained at 24 h.
U0126 tended to reduce this increase, although this was not significant. Results are shown as Whiske box plots (n = 4–5). (D) A co-immunoprecipitation
experiment used 25 μg total protein (3 h IR + vehicle) as input and 5 μg mouse mAb anti-ET-1 (Abcam, ab2786) as the immunoprecipitating antibody.
Western blot analysis was performed to detect the ETAR using Sigma pAb rabbit-anti-ETAR #9780 1:500. Specific ETAR-like immunoreactivity was
observed for the low molecular weight band (30 kDa).
https://doi.org/10.1371/journal.pone.0174119.g005
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pathway. The MEK-inhibitor (U0126) attenuated ET-1 expression and ETB receptor expres-
sion in post-ischemic hearts. Analysis of serum troponin levels 24 h after IR revealed a strong
increase while at this early stage after the ischema U0126 did not reduce this significantly. This
response is not unexpected because in methods of global cerebral ischemia (Johansson et al.,
2014) and in experimental subarachnoid hemorrhage (Edvinsson and Povlsen, 2011) the
MEK1/2 inhibition had a pronounced effect on late cerebral ischemia and on neurology out-
come and survival several days after the injury. We hypothesise that the coronary ischemia
approach may reveal a similar long-term effect on heart function and this deserves future
analysis.
The ET system in the circulation has a clear role in human pathophysiology with (i) expres-
sion in myocardium and coronary vasculature and (ii) association with e.g. hypertension,
Fig 6. (A) The mRNA expression levels of ETBR in the myocardium and left anterior descending artery (LAD) homogenates in sham, ischemia-reperfusion
(IR), and IR+U0126 treated rats at 3 h of IR resulted in up-regulated ETBR mRNA compared to sham. After U0126 treatment, there was no significant
upregulation as compared to sham (n = 5–8) (one-way ANOVA with Bonferroni’s multiple comparison test). (B) Western blot analysis revealed an ETB
receptor band at approximately 50 kDa. Quantification of ETB receptor immunoreactivity (normalized to GAPDH) revealed increased ETB receptor protein
levels (P < 0.05) at 3 h in the IR group compared to the sham group. This was normalized in the U0126 treated group. No significant differences were found
between the remaining groups (one-way ANOVA). (C) Immunohistochemistry of the 24 h IR group showed the localization of ETBRs in the endothelium
(arrow) of sham operated rats. In the IR+vehicle group, immunoreactivity in the VSMCs (arrow heads) in addition to the endothelium (arrow) was found. In
contrast, ETBR staining was absent in the VSMCs of the IR+U0126-treated rats.
https://doi.org/10.1371/journal.pone.0174119.g006
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heart failure, kidney disease and diabetes (Davenport et al. 2016). Circulating levels of the
strong and potent ET-1 is increased in myocardial infarction [14,26]. Further, plasma ET-1
concentrations are strongly linked to outcome after myocardial infarction and can provide
information that is associated with a poor prognosis [27] as well as to congestive heart failure
[28]. Enhanced ET-1 levels during heart ischemia may result in increased coronary artery tone
and that may further impair coronary blood flow. Synthesis of the biologically active 21-amino
acid ET-1 peptide is a multi-step process where the transcriptional regulation of the ET-1 gene
(edn1) is thought to be the major mechanism controlling ET-1 bioavailability [29]. Both hyp-
oxia and increased shear stress, important factors in ischemia and reperfusion, are known to
increase ET-1 expression and release [30–32]. Many signaling pathways are involved in edn1
gene regulation, including pathways that include protein kinase C and the MAPKs JNK and
ERK1/2 [33,34]. Here we report that ET-1 itself was up-regulated in the myocardium and in
the walls of coronary arteries after IR. In addition, treatment with U0126 reversed the increase
in ET-1, which is novel and strongly suggests that signaling via the MEK-ERK1/2 pathway is
involved in transcriptional up-regulation of ET-1 in the myocardium after IR.
Freshly isolated and healthy rat coronary arteries show negligible ETB receptor-mediated
contractions [35,36] but can induce relaxation via endothelin ETB receptors. In ischemia there
is a phenotypic shift and vasoconstrictor endothelin ETB receptors are expressed in tissues
affected by cardiovascular diseases [22]. In the present study, non-ischemic coronary arteries
Fig 7. Serum Troponin T measurements in sham operated, IR+vehicle and IR+U0126 (n = 6 in each
group). ***P < 0.001, by one-way ANOVA followed by Bonferroni’s multiple comparison test.
https://doi.org/10.1371/journal.pone.0174119.g007
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displayed negligible vasoconstrictor responses to S6c, while post-ischemic arteries showed
strong concentration-dependent constriction. The enhanced ETB receptor-mediated vasocon-
strictor responses in the downstream LAD were evident at 24 h [23]. The enhanced ETB recep-
tor mRNA expression was verified by qPCR already at 3 h of reperfusion, and the ETB receptor
protein up-regulation was seen to occur in VSMC by immunohistochemistry at 24 h. Up-regu-
lation of functional ETB receptors may take several hours, as shown in an ex vivo organ culture
method, and ETB receptor up-regulation involves activation of the MEK-ERK1/2 signaling
pathway [24]. The present study demonstred this in vivo using the specific MEK1/2 inhibitor
U0126. After treatment with U0126, the up-regulation of vasoconstrictor ETB receptors was
abolished at 24 hours, which is in concert with the immunohistochemistry results.
The endogenous ligand to endothelin receptors ET-1 has equally high affinity for ETA and
ETB receptors [37]. Since ETB receptors desensitize rapidly upon S6c binding [38], we were
able to distinguish between ETA and ETB receptor mediated vasoconstrictor responses by first
stimulating ETB receptors with the specific agent S6c and, after desensitization of ETB recep-
tors, blocking the remaining ETB receptors with BQ788 (Adner et al. 1996). We then measured
ETA receptor-mediated vasoconstriction using ET-1 and found that ETA receptor-mediated
responses remained unaffected in post-ischemic coronary arteries at 24 h after IR. Interestingly
we observed two main ETAR-like immunoreactive bands in our Western blot analysis. The
upper band, which corresponds to full-length ETAR (426 aa) at approximately 45 kDa, did not
show any significant changes in expression level regardless of IR, treatment, or duration of
reperfusion. In contrast, the low-molecular weight band, at approximately 30–33 kDa, showed
a strong trend towards upregulation during the initial phase after IR, and this persisted after
24 h. The nature of the latter band remains unclear, but a pilot co-IP reaction (Fig 5D) identi-
fied this band as the primary co-immunoprecipitated protein when the reaction was per-
formed with a monoclonal antibody against ET-1/prepro-ET-1 followed by blotting to detect
the ETA receptor. In contrast, qPCR analysis did not reveal any global changes in ETA receptor
mRNA. This analysis utilized a primer set located within exon 2, which contains part of the 5’-
UTR, the signal peptide sequence, and the first 120 amino acids of the receptor. As the signal
peptide is likely to be crucial for membrane insertion, this exon is probably contained in all
putative splice variants of ETA. Thus, the primer set should measure the combined pool of ETA
mRNA transcripts. In addition, if the up-regulation we observed was mainly due to changes in
the rate of translation, no changes in mRNA levels would be expected. A number of ETA recep-
tor splice variants have been reported [39–43], few of which have been confirmed as functional
proteins [40]. Most studies report a truncated version in which exons 3 and/or 4 have been
spliced out, resulting in proteins with 2 to 5 transmembrane domains. In the absence of exons
3 and 4, this would produce a peptide of the size observed in this study; however, this truncated
version, when expressed in CHO cells, did not show any binding affinity for either ET-1 and
ET-3 [41]. Given the robust changes we observed in the low-molecular weight band and the
reported presence of various splice variants of the ETA receptor, we speculate that this band
may be a novel ETA receptor splice variant that retains ET-1 binding capacity but lacks vaso-
constrictive effects. Further studies are needed to confirm this.
Occlusion of a coronary artery results in insufficient flow to the contracting myocytes and,
if the ischemia is prolonged, it results in myocardial cell death. Rapid PCI can restore epicar-
dial blood flow, but has some drawbacks. Although reperfusion reduces infarct size and
enhances survival, it may in itself result in reversible injury, stunning, arrhythmias, and irre-
versible reperfusion injury. Thus, reperfusion may account for about 50% of the final infarct
size [44]. Hence, our main aim with this study was to evaluate if the occlusion and reperfusion
of LAD might be associated with alterations in the expression of ET-1 and its receptors, and if
inhibition of this upregulation might modify the resulting tissue damage. Increased expression
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of the ET-1 ligand and its receptors, along with elevated vasoconstriction, may explain the
diminished blood flow, at least in part. A more detailed functional analysis of the long-term
consequences of the prevention of the vascular phenotypic shift in ET-1 and ETB receptor
expression, will be done using functional studies with high field MRI. Understanding the
underlying molecular mechanisms involved may provide novel ways to reduce tissue injury
after IR. We propose that inhibiting both the elevation of ET-1 and ETB receptor expression in
conjunction with IR could be beneficial in terms of improving coronary blood flow and atten-
uating coronary artery injury.
In summary, we found that treatment with the specific MEK1/2 inhibitor U0126 reduced
the early activation of pERK1/2 in the vessel wall after IR at 3 hrs and in addition attenuated
the de novo expression of both vasoconstrictor ETB receptors and the expression of ET-1 after
myocardial IR,. These novel findings suggest that the MEK-ERK signaling pathway is impor-
tant for regulation of ET-1 and ETB receptor expression and function in the myocardium and
coronary arteries after myocardial IR.
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